Person: Lu, Karen
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
First Name
Name
Search Results
Publication Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative
Hughes, Kevin; Wood, Marie; Kadlubek, Pamela; Pham, Trang; Wollins, Dana; Lu, Karen; Weitzel, Jeffrey; Neuss, MichaelPurpose: Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/ testing (GC/GT). Prior studies have demonstrated low rates of family history documentation and referral for GC/GT. Methods: CFH quality and GC/GT practices for patients with breast (BC) or colon cancer (CRC) were assessed in 271 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative in fall 2011. Results: A total of 212 practices completed measures regarding CFH and GC/GT practices for 10,466 patients; 77.4% of all medical records reviewed documented presence or absence of CFH in first-degree relatives, and 61.5% of medical records documented presence or absence of CFH in second-degree relatives, with significantly higher documentation for patients with BC compared with CRC. Age at diagnosis was documented for all relatives with cancer in 30.7% of medical records (BC, 45.2%; CRC, 35.4%; P .001). Referall for GC/GT occurred in 22.1% of all patients with BC or CRC. Of patients with increased risk for hereditary cancer, 52.2% of patients with BC and 26.4% of those with CRC were referred for GC/GT. When genetic testing was performed, consent was documented 77.7% of the time, and discussion of results was documented 78.8% of the time. Conclusion: We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed.
Publication Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle
(American Society of Clinical Oncology (ASCO), 2014-10-10) Wood, Marie E.; Lu, Karen; Wollins, Dana; Hughes, KevinWe agree with Hemminki et al1 that family history information can be used to identify individuals at both hereditary and familial cancer risk. We also agree that, in general, the percentage of any cancer type attributed to a familial form of cancer will be greater than the percentage that is likely hereditary. Hemminki et al point out that genetic testing is not yet available for those at familial risk.